TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug’s Efficacy Moves Forward -- Hagens Berman

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Hagens Berman
aTyr Pharma (ATYR) Posts Wider-Than-Expected Loss as Investor Litigation Over Key Drug’s Efficacy Moves Forward -- Hagens Berman

aTyr Pharma reported a wider-than-expected quarterly loss and is facing a securities class action lawsuit after its Phase 3 clinical trial for Efzofitimod failed to meet primary endpoints, causing an 83% stock price drop.

Insights
ATYR   negative

Company experienced significant stock price decline, missed financial estimates, failed clinical trial, and is now facing investor litigation over alleged misleading statements about drug efficacy